0.1131
Schlusskurs vom Vortag:
$0.1126
Offen:
$0.1149
24-Stunden-Volumen:
304.89K
Relative Volume:
0.47
Marktkapitalisierung:
$3.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.91M
KGV:
-0.0759
EPS:
-1.49
Netto-Cashflow:
-
1W Leistung:
-14.39%
1M Leistung:
-83.29%
6M Leistung:
-95.90%
1J Leistung:
-95.55%
Incannex Healthcare Inc Stock (IXHL) Company Profile
Firmenname
Incannex Healthcare Inc
Sektor
Telefon
61 409 840 786
Adresse
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
Vergleichen Sie IXHL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IXHL
Incannex Healthcare Inc
|
0.1131 | 3.66M | 0 | -21.91M | 0 | -1.49 |
![]()
ZTS
Zoetis Inc
|
159.81 | 69.43B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.79 | 46.56B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.19 | 20.71B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
305.07 | 13.25B | 2.76B | 1.11B | 898.10M | 22.77 |
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Incannex Healthcare Inc [IXHL] Revenue clocked in at $0.10 million, down -92.83% YTD: What’s Next? - dbtnews.com
It makes sense and dollars to buy Incannex Healthcare Inc (IXHL) stock - Sete News
Analyzing the Impact of Earnings Reports on Incannex Healthcare Inc Inc. (IXHL) Price Performance - investchronicle.com
Is Incannex Healthcare Inc (NASDAQ:IXHL) stock a better investment at this time? - uspostnews.com
Trading Day Review: Incannex Healthcare Inc (IXHL) Gains Momentum, Closing at 0.61 - DWinneX
Incannex Healthcare (NASDAQ:IXHL) Trading Down 19% – Here’s Why - Defense World
Incannex enters agreement for potential stock sales By Investing.com - Investing.com India
Incannex enters agreement for potential stock sales - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.64 Amid Market Challenges - Investing.com
Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa) - MarketScreener
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) - TradingView
Revolutionary Once-Daily Pill for Sleep Apnea Hits Major Clinical Trial Milestone - Stock Titan
IXHL stock touches 52-week low at $0.73 amid market challenges - Investing.com
Incannex Healthcare files to sell 65.97M shares of common stock for holders - MSN
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Decrease in Short Interest - The AM Reporter
Incannex Healthcare Repays Convertible Debenture in Full - TipRanks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges - Investing.com Australia
IXHL Stock Touches 52-Week Low at $0.73 Amid Market Challenges By Investing.com - Investing.com South Africa
Incannex Healthcare announces $12.5 million offering - Green Market Report
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules - The Manila Times
Incannex Healthcare Inc. Announces Pricing Of $12.5 Million Private Placement Priced At The Market Under Nasdaq Rules - Marketscreener.com
Incannex Healthcare Inc. Announces $12.5 Million Offering of Common Stock and Series A Warrants - Nasdaq
Can This $12.5M Deal Push Incannex's Sleep Apnea Treatment to Phase 3? - StockTitan
IXHL stock touches 52-week low at $1.09 amid market challenges - Investing.com Australia
Incannex OSA Drug Candidate IHL-42X Sails Through Milestones - Sleep Review
IXHL stock touches 52-week low at $1.49 amid market challenges By Investing.com - Investing.com South Africa
IXHL stock touches 52-week low at $1.49 amid market challenges - Investing.com UK
Incannex Healthcare Limited Reports Quarterly Financials - TipRanks
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 - The Kingston Whig-Standard
Biotech Earnings Alert: Incannex Secures $50M Financing as R&D Costs Drop 46% - Stock Titan
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates - Defense World
Incannex Healthcare Reports Fiscal Second Quarter Results -February 14, 2025 at 08:49 am EST - Marketscreener.com
Incannex Healthcare Inc. SEC 10-Q Report - TradingView
Incannex Healthcare Appoints Alison Wimms, Ph.D. to its Newly Formed IHL-42X Obstructive Sleep Apnea Clinical Advisory Board - Defense World
Incannex Forms Clinical Advisory Board to Guide IHL-42X Sleep Apnea Drug Development - Sleep Review
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board - The Manila Times
Incannex Healthcare Inc. Announces the Appointment of Alison Wimms as an Advisor to Its Newly Formed Ihl-42X Obstructive Sleep Apnea Clinical Advisory Board - Marketscreener.com
Sleep Medicine Pioneer Joins Incannex's Revolutionary OSA Treatment Development - StockTitan
Incannex Healthcare Announces Positive Topline Results from PK Study - Defense World
Incannex Reports Positive Data for OSA Drug Candidate IHL-42X - Sleep Review
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea - The Manila Times
Incannex Reports Strong Results for Sleep Apnea Drug IHL-42X in Key Clinical Study - StockTitan
Incannex Healthcare faces Nasdaq delisting over market value By Investing.com - Investing.com South Africa
Incannex Healthcare faces Nasdaq delisting over market value - Investing.com
Finanzdaten der Incannex Healthcare Inc-Aktie (IXHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):